Seminal vesicle biopsy in prostate cancer staging

• Published in: The Journal of urology Vol. 154; no. 4; p. 1407
• Main Authors: Allepuz Losa, C A, Sanz Velez, J I, Gil Sanz, M J, Mas, L P, Rioja Sanz, L A
• Format: Journal Article
• Language: English
• Published: United States 01.10.1995
• Subjects: Aged; Biopsy; False Negative Reactions; False Positive Reactions; Genital Neoplasms, Male - pathology; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prostate-Specific Antigen - blood; Prostatic Neoplasms - blood; Prostatic Neoplasms - pathology; Seminal Vesicles - pathology; Sensitivity and Specificity
• DOI: 10.1016/s0022-5347(01)66878-2
• ISSN: 0022-5347

Prostate cancer patients were differentiated using seminal vesicle biopsies related to clinical staging, prostate specific antigen (PSA), Gleason scores and PSA density values. A total of 75 patients underwent seminal vesicle biopsies. Patients with no seminal vesicle invasion and negative lymphadenectomy results underwent radical prostatectomy. Efficacy of seminal vesicle biopsy was 90.9%. Infiltration rates were 69% for disease stage T2b or greater, 68% for PSA greater than 10 ng./ml., 78% for PSA greater than 20 ng./ml. and 73% for type 4 and/or 5 Gleason scores. For the prognosis of seminal vesicle invasion, 0.40 was the best PSA density cutoff point. We recommend seminal vesicle biopsy in patients with stage T2b or greater disease, and with a lower clinical stage when the PSA level is 20 ng./ml. or greater and/or the Gleason score is 7 or greater.